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ABSTRACT 48 
Objectives Venous percutaneous transluminal angioplasty (vPTA) in patients with multiple 49 
sclerosis (MS) and chronic cerebrospinal venous insufficiency (CCSVI) have shown 50 
contradictory results. Aim of the study is to evaluate the efficacy of the procedure in a 51 
randomized wait list control study. 52 
Materials: 66 adults with neurologist-confirmed diagnosis of MS and sonographic diagnosis 53 
of CCSVI were allocated in to vPTA-yes group (n=31) or vPTA-not group (n=35, control 54 
group). Venous PTA was performed immediately 15 days after randomization in PTA-yes 55 
group and 6 months later in the control group. 56 
Methods: Evoked potentials (EPs), clinical-functional measures (CFM) and upper limb 57 
kinematic measures (ULKM) were measured at baseline (T0) and six months after in both 58 
groups, just before the venous angioplasty in vPTA-not group (T1). 59 
Results: Comparing vPTA-yes and vPTA-not group, the CFM derived composite functional 60 
outcome showed 11(37%) versus 7(20%) improved, 1(3%) versus 3(8%) stable, 0 versus 61 
7(20%) worsened and 19(61%) versus 18(51%) mixed patients (χ2=8.71, df=3, p=0.03). 62 
Unadjusted and adjusted (for baseline confounding variables) OR at 95% confident interval 63 
(95%CI) were respectively 1.93(1.3-2.8) P-value 0.0007 and 1.85(1.2-1.7) P-value 0.002. 64 
EPs and ULKM derived composite functional outcome showed no significant difference 65 
between the two groups. 66 
Conclusions: Venous angioplasty can positively impact a few CFM especially for the quality 67 
of life, but achieving disability improvement is unlikely. 68 
Keywords: Multiple Sclerosis; Chronic Cerebrospinal Venous Insufficiency; Angioplasty; 69 
Endovascular Procedures 70 
  71 
 4
 72 
INTRODUCTION 73 
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 74 
nervous system with a disabling progressive course. Chronic Cerebrospinal Venous 75 
Insufficiency (CCSVI) has been recognized as truncular venous lesions with obstructing 76 
characteristics localized in the territory of internal jugular veins (IJVs) and/or vertebral veins 77 
(VVs)1. Available clinical studies, about the CCSVI and the potential effects of corrective 78 
venous PTA, show contradictory results and do not provide evidence of the efficacy of the 79 
treatment2-6. Only a few randomized sham-controlled intervention studies have been 80 
published7-8.  Furthermore, improvement has been reported relating to subjective symptoms 81 
such as headache, fatigue and depression, which could not be detected with the commonly 82 
used expanded disability status scale (EDSS)9-12. Following the resolution issued by the 83 
Italian Superior Health Council in February 2011 and spurred by public opinion, the 84 
Directorate of tertiary referral center activated a care pathway aimed at clarifying the clinical 85 
effectiveness of venous Percutaneous Transluminal Angioplasty (vPTA) in patients with MS 86 
and CCSVI. A local collaborative team constituted by specialists relating to neurology (FS, 87 
TB), neuro-rehabilitative section (MCC, RB), radiology (VN, DC), interventional radiology 88 
(OP, RC), statistic (RM) and vascular surgery (RB, MM, NM, CC, MF) units was endorsed. 89 
A randomized controlled clinical study was carried out once local ethical committee 90 
approved the study protocol. 91 
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METHODS 93 
Design 94 
This study was a randomized and wait list, not-sham (not intervention) controlled clinical 95 
study to evaluate the efficacy of vPTA in patients with MS and CCSVI. A wait list design 96 
was conceived: half of the participants were randomly assigned to receive vPTA early 97 
(vPTA-yes group) and half of the participants were randomly assigned to receive it later 98 
(vPTA-not group) (Fig 1). Simple type 1:1 randomization was performed by an external 99 
structure. All patients had a baseline evaluation (T0) and the second evaluation (T1) six 100 
months after in both groups, just before the venous angioplasty in vPTA-not group. The 101 
clinical study started in September 2011 and closed in September 2016. For clinical study 102 
safety the stopping rules included serious adverse events and their types and grades are 103 
reported according to the Good Clinical Practice guidelines. 104 
 105 
Patients 106 
418 patients requesting vPTA were registered, but only in 161(38.5%) the diagnosis of MS 107 
was confirmed by neurologists following McDonald criteria13.  108 
A total number of 161 patients underwent echo-color Doppler (ECD) ultrasonography in 109 
sitting and supine position. The ECD examination protocol for the diagnosis of CCSVI was 110 
obtained following the methodology proposed by Zamboni 14-16. Out of 161 patients, 111 
47(29.2%) had normal ultrasonographic findings, and 114 patients (70.8%) had CCSVI. Out 112 
of these 114 participants, 48(42.1%) declined to participate, so 66(57.9%) were included in 113 
the randomization phase; MS course of the enrolled patients was: relapsing-remitting (RR) 114 
37(56.1%), secondary progressive (SP) 13(19.7%) and primary progressive (PP) 16(24.2%) 115 
(Fig 1). 116 
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The inclusion criteria were: age within 18-65 years; diagnosis of MS with any kind of disease 117 
course and any disability level16-18; diagnosis of CCSVI by ECD exam14-16. The exclusion 118 
criteria were: age less than 18 years or more than 65 years; patients unable to provide 119 
informed consent; the presence of other pathologies of the central nervous system other than 120 
MS; clinical relapses and therapy with steroids in the 30 days before the procedure; patients 121 
not willing to strictly adhere to the study design and to follow the expected controls; the 122 
presence of pregnancy or lactation; life expectancy of less than one year; inadequate temporal 123 
acoustic window at intracranial ECD exam; the arbitrary use of new pharmacological 124 
treatments. Previous vPTA was not considered an exclusion criterion. 125 
 126 
Ultrasonographic diagnosis of CCSVI  127 
CCSVI assessment was performed by a single operator (VN) certificated at Zamboni’s center 128 
training. All the ultrasound examinations were carried out using CCSVI Protocol MyLab 129 
Vinco (Esaote S.p.A, Florence, Italy) equipped with a linear transducer of 3.5–10MHz for 130 
extracranial veins evaluation and a phased array transducer of 2,0-3,3 MHz for intracranial 131 
veins assessment. The presence of at least 2 of 5 Zamboni’s morpho-functional specific 132 
criteria related to internal jugular veins (IJVs) or vertebral veins (VVs) visualized in both 133 
supine and sitting positions was used to diagnose CCSVI and select patients for the 134 
randomization procedure19-20. 135 
Therefore the presence of the five ultrasound diagnostic criteria, such as:  136 
1) reflux in the IJVs and/or VVs,  137 
2) reflux in the intracranial veins,  138 
3) high-resolution B-mode evidence of IJVs stenosis and/or other B-mode anomalies,  139 
4) absence of flow in the IJVs and/or VVs,  140 
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5) cross-sectional area (CSA) of the IJV measured in sitting position larger than to that 141 
obtained in supine position,  142 
was investigated in all MS patients. No muscular entrapment was detected. 143 
Patients were submitted the day after the procedure and after 30 days to an ultrasound 144 
examination to exclude complication such as vein thrombosis. 145 
 146 
Technical and inter-procedural details of the vPTA 147 
Patients allocated into vPTA-yes group received the dilative vPTA immediately 15 days after 148 
randomization and the patients allocated into control, not-sham, group underwent 149 
interventional procedure 6 months later.  150 
The interventional procedures were executed using two angiographic device (GE INNOVA 151 
4100 Cath/Angio Suite and GE Healthcare InnovaTM IGS 540 Image Guided System) in a 152 
room prepared for angiography and interventional radiology. This device allowed the 153 
acquisition of multiple two-dimensional images along a circular trajectory greater than 180°.  154 
The same team whose members were certificated at Zamboni’s center training carried out all 155 
the interventional procedures (OP, RC). Local anesthesia at venous access site was performed 156 
in all patients. The 2D projections obtained were converted in axial images similar to those of 157 
the TC with a reconstruction algorithm 3D cone-beam. Patient preparation was considered 158 
completed only when the informed consent was obtained and local anesthesia in groin area 159 
and systemic heparinization (5000 UI of sodium heparin in 48/55 patients and 7500 UI in 160 
7/55 patients) were administrated.  161 
Diagnostic procedure was made up of:  162 
1) placement of a 15 cm long valvular introducer 7-9 Fr (Cordis®, AVANT+ introducer, 163 
Cordis Cashel, chair Road Cashel. Co Tipperary. Ireland) in the femoral vein with Seldinger 164 
technique;  165 
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2) ascending catheterization (recommended with catheter 4Fr Radifocus® Glidecath® - 166 
Hydrophilic Angiographic Catheter, Vertebral/ Simmons/Sidewinder1; Cordis®, SIM 1, 167 
Super Torque®; Cordis®, H1, Super Torque®) of the left ileolumbar (IL) vein followed by 168 
the phlebography (mdc injection: 20-30 ml, 4 ml/s) of the lumbar district in postero-anterior 169 
projection which aims to study the paravertebral vein circulation. If the catheterization of the 170 
left IL is complicated, could be catheterized a lateral sacral vein or directly a lumbar vein;  171 
3) superior vena cava (SVC) catheterization and manometry;  172 
4) azygos vein catheterization, manometry and phlebography in postero-oblique projection 173 
(mdc injection: 10-30 ml, 3-8 ml/s);  174 
5) internal jugular vein (IJV) manometry, and phlebography in postero-anterior and oblique 175 
projection after the placement of the catheter at the level of the mandibular angle (mdc 176 
injection: 8 ml, 3 m/s). It was advisable to let the patient breathe deeply and make the 177 
Valsalva maneuver, because these procedures help the venous outflow and the valves 178 
opening;  179 
6) vertebral veins retrograde catheterization and phlebography with manual injection. 180 
The vPTA was executed with adequate size compliant balloon catheters at level of stenosis in 181 
extra cranial and azygos veins. In case of significative stenosis was performed an invasive 182 
evaluation of the pressure and the trans-stenotic pressure gradient.  183 
The interventional procedure of azygos vein was made up of:  184 
1) vPTA with compliant balloon catheters (Wanda™ PTA Balloon / Atlas® GOLD PTA 185 
Dilatation Catheters): 8-12 mm (caliber), 2-4 cm (length) inflated with a maximum of 14-18 186 
atm, the insufflation lasts for 30-60 sec and is repeated several times;  187 
2) phlebography and manometry control of the azygos after the vPTA. 188 
The interventional procedure of internal jugular veins was carried out by:  189 
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1) PTA with compliant balloon catheters (Wanda™ PTA Balloon / Atlas® GOLD PTA 190 
Dilatation Catheters): 10-22 mm (caliber), 2-6 cm (lenght) inflated with a maximum of 18 191 
atm,  192 
2) dilatation with not compliant balloons (Atlas® GOLD PTA Dilatation Catheters) inflated 193 
with high pressure (18-20 atm), the insufflation lasts for 30-60 sec and it is repeated several 194 
times if post-procedure result was not sufficient; phlebography and control manometry of the 195 
jugular veins after the angioplasty was performed. 196 
The interventional procedure of vertebral veins was carried out by means of vPTA with 197 
compliant balloon catheters (Wanda™ PTA Balloon/ Atlas® GOLD PTA Dilatation 198 
Catheters): 8-10 mm (caliber), 2-4 cm (length) inflated with a maximum of 8 atm. We used 199 
balloons with length between 20-60 mm (mean 45 mm; median 40 mm) and caliber between 200 
8-22 mm (mean 12 mm; median 10 mm), in all patients after the procedure a pressure 201 
evaluation was performed in basal conditions and during Valsalva maneuver. 202 
 203 
Functional Outcome 204 
Several neurophysiological and functional tests were used to consider the efficacy of the 205 
vPTA. Three categories of tests were arranged: (1) evoked potentials (EPs) tests, (2) clinical-206 
functional measures (CFM) and (3) upper limb kinematic measures (ULKM).Evoked 207 
potentials (EPs) evaluation was performed by both visual evoked potentials (VEPs) and 208 
motor evoked potentials (MEPs). An independent blinded neurological assessor was involved 209 
for each category of tests (EPs, CFM and ULKM). 210 
Each single test was classified as worsened, improved or stable on the basis of the relative 211 
change (arbitrarily set at 20%) found at T1 when compared to T0; a test was improved or 212 
worsened if the variation was at least 20%, stable if otherwise. 213 
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A derived composite functional outcome for each category of EPs, CFM, and ULKM tests 214 
was designed by aggregating similar single functional tests in the same category. Thus, a 215 
composite functional endpoint for EPs, CFM and ULKM tests was used and accordingly each 216 
of enrolled patient could be classified as worsened (W) if some tests showed worsening, 217 
stable (S) if no change in all tests, improved (I) if some tests showed improvement and mixed 218 
(M) if there was a mixture of worsened and improved tests. The proportion of improved 219 
patients from each derived composite functional outcome was estimated between the two 220 
groups of treatment. 221 
 222 
Statistical analysis 223 
Analysis was carried out on an intention-to-treat basis. The effect of vPTA versus control on 224 
each EPs, CFM and ULKM composite functional outcome was assessed by comparing the 225 
proportion of improved patients at T1 in both vPTA-yes and vPTA-not groups. Significance 226 
of differences in proportion was assessed by χ2 test. 227 
As the estimate of the effect size, odds ratio (OR) at 95% confident interval (95%CI) was 228 
considered appropriate to verify the relationship between treatment group predictor variables 229 
and response outcome variables. For each EPs, CFM and ULKM composite functional 230 
outcome, both unadjusted and adjusted OR were assessed. Adjusted logistic model was used 231 
for gender, MS course, both T0 and T1 EDSS raw data scores, both T0 and T1 EDSS >3.5 232 
and interactions. Possible co-existing correlation between rate of EDSS variation and Venous 233 
Hemodynamic Insufficiency Severity Score (VHISS) variation after vPTA was not assessed. 234 
Detailed results concerning baseline tests values (raw data scores) at T0 and T1 for 235 
components of each EPs, CFM and ULKM composite functional outcome in vPTA-yes group 236 
were also evaluated. Both matched-pairs t-test and Wilcoxon signed-rank test with continuity 237 
correction were used to compare pre- and post-vPTA measurements in paired observation. 238 
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For statistical significance P-value <0.05 and two-sided test were used. Adjusting for 239 
multiple comparisons using Hommel method (reported as adjusted P-value) was applied 240 
when components of each derived composite functional outcome was analyzed21. 241 
All statistical analyses were carried-out with JMP 7.0 (2007 SAS Institute Inc.) and R 3.3 242 
software22, 23.    243 
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RESULTS 244 
Baseline patients’ characteristics did not show difference between the two groups (Table 1). 245 
Sites for venous angioplasty in vPTA-yes group were: monolateral jugular vein 5(16%); 246 
bilateral jugular veins 26(84%); jugular plus azygos veins 2(6%). No venous angioplasty was 247 
performed in vertebral veins.  248 
Results for each EPs, CFM and ULKM composite functional outcome are summarized in 249 
Table 2.  When EPs and its derived composite functional outcome in the vPTA-yes versus 250 
vPTA-not group were analyzed, unadjusted and adjusted OR (95% CI) for treatment group 251 
predictor variable were respectively 1.03 (P-value 0.82) and 1.26 (P-value 0.18). However, 252 
while at final logistic adjusted model the treatment group predictor variable had no 253 
significant effect, but the MS course (especially the PP phenotype), both T0 and T1 EDSS 254 
raw data scores, EDSS >3.5 at T1 showed significant effect: OR=1.7(P-value 0.03) (MS 255 
course PP/RR); OR=2.1 (P-value 0.007) (MS course PP/SP); OR=4.04(P-value 0.0019) (T0 256 
EDSS raw data scores); OR=0.14(P-value 0.0001) (T1 EDSS raw data scores); OR=4.4(P-257 
value 0.0004) (EDSS>3.5 at T1). 258 
The CFM and its derived composite functional outcome in the vPTA-yes versus vPTA-not 259 
group showed an unadjusted and adjusted OR (95% CI) for treatment group predictor 260 
respectively of 1.93(P-value 0.0007) and 1.85(P-value 0.002). However, at final logistic 261 
adjusted model both T0 and T1 EDSS raw data scores were also significant predictors: 262 
OR=4.03(P-value 0.007)(T0 EDSS raw data scores); OR=0.22(P-value 0.003)(T1 EDSS raw 263 
data scores). 264 
The ULKM and its derived composite functional outcome in the vPTA-yes versus vPTA-not 265 
group showed an unadjusted and adjusted OR (95% CI) for treatment group predictor 266 
variable respectively of 1.16(P-value 0.5) and 1(P-value 0.96). While at final logistic adjusted 267 
model the treatment group predictor variable was not significant however both T1 EDSS raw 268 
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data scores and EDSS>3.5 at T1 had a significant main effect: OR=1.3(P-value 0.008)(T1 269 
EDSS raw data scores); OR=0.28(P-value 0.01)(EDSS>3.5 at T1). 270 
Detailed results for each EPs, CFM and ULKM composite functional outcomes are provided 271 
in Table 3, 4, 5. 272 
Both paired-t-test and Wilcoxon signed rank test with continuity correction for matched pairs 273 
in the PTA-yes group demonstrated significant results for urinary urgency (#31 test), quality 274 
of life (QoL) physical (#43 test) and mental (#44 test), and MDE with right arm (#45 test). 275 
However only the mental QoL test remained significant after P-value adjustment for multiple 276 
comparisons. 277 
 278 
DISCUSSION 279 
The vPTA has been proposed as a valid treatment option in patients with MS and CCSVI. 280 
This procedure has been suggested to potentially improve the clinical course of MS (relapse 281 
rate) and quality of life. Positive aspects emerging from current evidence are the 282 
improvement of MS course and potential modulation of MR lesion dissemination and activity 283 
6 months after treatment. Defined negative aspects include inadequate disability 284 
improvement8. vPTA might be a useful intervention for treating patients with persistent 285 
headaches10. These changes cannot be detected with the commonly used EDSS score system 286 
for disability. Recognized drawbacks are its ineffective role in restoring blood flow in nearly 287 
half the patients in case of muscular entrapment or compression, hypoplasia, very long 288 
abnormal leaflets as well as restenosis. Finally effects could be not long lasting24. 289 
The present study was conceived to verify the efficacy of vPTA in patients having both MS 290 
and CCSVI in terms of different clinical outcomes and to offer free services for MS patients 291 
in highly specialized center, which would otherwise have been provided by many hospitals 292 
for a fee, both in Italy and in other countries. The randomization and a wait list allowed 293 
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generating the control group (vPTA-not group, n=35) and treatment group (vPTA-yes group 294 
n=31). In fact within the time of the wait list all patients allocated in the control group 295 
underwent two consecutive measurements of outcome (T0 and T1) before the completion of 296 
vPTA, while all patients allocated in the treatment group underwent a baseline evaluation 297 
(T0) before vPTA and the second evaluation (T1) after vPTA. Therefore the only difference 298 
between the two groups was the completion of the radiological procedure in the treatment 299 
group and the lack of the vPTA in the control group. 300 
Our results concerning CFM derived composite functional outcome showed significant 301 
improvements of some clinical functional aspects, such as fatigue, pain, quality of life both 302 
mental and physical, anxiety, depression, attention and urinary urgency. There was no 303 
improvement in motor function after treatment, except for TUG test. These results confirm a 304 
previous study, where vPTA had no positive effects on motor disability8. However, other 305 
studies demonstrated improvement in fatigue, numbness, balance, concentration and memory, 306 
and mobility10-12 as well as in physical and psychological performance items of the MSIS-299, 307 
25
. Although 6 months follow-up was performed in both studies, in Sadovnick’s study24the 308 
improvements were transient and progressively decreased, while in Hubbard’s study9 they 309 
were maintained. These studies were based on the patients’ self-reported outcome instead of 310 
objective outcomes derived from physicians’ clinical scales. However, the improvement 311 
priority and aim could be unequal in physician or patients’ points of view. A recent study26 312 
reported that patients’ concerns about quality of life are not always the same as the 313 
physicians’. In another study27, MS patients considered pain the most relevant aspect about 314 
health perception, which was followed by gait impairment and fatigue. The authors 315 
concluded that what they supposed to be the “invisible disability” could be more relevant to 316 
health perception than motor disability in MS patients. 317 
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One point of strength of our study is the neurophysiological assessment. To the best of our 318 
knowledge published results about the behaviour of VEPs in MS patients who had venous 319 
angioplasty have not previously been evaluated, and only one case report has assessed MEPs 320 
changes over time28. Classically, VEPs and MEPs are considered functional predictive 321 
biomarkers for therapeutic responses because neurophysiological scores are bi-directional, 322 
covering both improvement and deterioration29. Overall, EPs evaluation may help to provide 323 
early differentiation between possibly effective and needless interventions in phase-II clinical 324 
trials30-33. Despite a slight tendency to improvement when some tests were analysed 325 
separately, EPs composite functional outcome did not significantly change. That seems to fit 326 
with the lack of a clear disability improvement in clinical scales.  327 
In our study the MS course was not considered an exclusion criteria and there are not any 328 
significantly unbalanced proportion between the two groups. Nevertheless our results showed 329 
a significant effect of MS course, especially the PP phenotype, when EPs and its derived 330 
composite functional outcome in the vPTA-yes group at final adjusted logistic model was 331 
considered (OR=1.7, P-value 0.03, MS course PP/RR and OR=2.1, P-value 0.007, MS course 332 
PP/SP). However caution in the interpretation is needed taking into account of the small 333 
number of cases enrolled. 334 
Medical therapy was not included as predictor in the adjusting logistic model; therapy with 335 
steroids in the 30 days before the procedure and the arbitrary use of new pharmacological 336 
treatments were exclusion criteria. 337 
Venous angioplasty for CCSVI is considered a safe procedure but adverse events can 338 
occur24,34-37.  In our study vPTA produced major complications such as acute in-segment IJV 339 
thrombosis in 3(9.6%) cases, minor complications such as puncture site bleeding in 1(3%) 340 
case. There were no serious adverse events. These cases of acute IJV segment thrombosis 341 
referred to patients in whom either complete stenosis with no valid hemodynamic flow or 342 
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hypoplasia was revealed at catheter phlebography and ECD. Since we prolonged the time of 343 
heparin administration from 15 to 40 days such a complication was solved without clinical 344 
consequences. Hypoplasia of IJV segments is considered a relative contraindication to 345 
venous angioplasty because of scarce angiographic response and high thrombotic risk. Open 346 
surgery has been invoked as alternative procedures38. Coagulation activation and endothelial 347 
dysfunction could have also played a significant role in this particular complication39.  348 
Several limitations of this study should be considered. Both difficulties in enrolling a 349 
sufficient sample size, despite 5 years devoted to that purpose with high cost, and lack of 350 
blinding or not-sham control could entail underpowered and biased results. Sham control 351 
trials and wait list control trial could be considered similar in that there are often potential 352 
problems of lack of blinding. It was thought that patients of sham control group could realize 353 
that their intervention time was different from standard procedure, despite the radiologists’ 354 
best efforts to mask it, and from there deduce that they had received placebo. Besides, 355 
patients allocated in sham control group had to undergo a potential harmful procedure. 356 
Although frequently used for ethical advantages, a wait list design can pose several issues in 357 
this particular clinical setting: first, the effects of being in a wait list control condition in 358 
interventional procedure research have not previously been evaluated40; second, participants 359 
who are going to receive their treatment sooner could be better motivated and comply better 360 
with the treatment programs and report better outcomes41-42.  361 
Finally, another limitation of our study is the lack of an adequate follow-up, which needed to 362 
be consistent and long enough to verify the progression of the disease. The improvements we 363 
found were only present at one month after procedure and nothing can be said about the long-364 
term effects and restenosis of vPTA in MS patients with CCSVI. 365 
In conclusion, patients with MS and CCSVI treated with vPTA showed significant 366 
improvements of some clinical functional aspects, such as fatigue, pain, quality of life both 367 
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mental and physical, anxiety, depression, attention and urinary urgency. Evoked potentials 368 
and upper limb kinematic measures were not significant enough to allow the evaluation of the 369 
efficacy of the procedure. vPTA can have a positive impact on a few neurological tests 370 
including quality of life but achieving disability improvement is unlikely. 371 
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Table 5. Detailed results for single components of Upper Limb Kinematic Measures (ULKM) 
composite functional outcome. 
 
 
Tables 
Table 1. Demographic and clinical features of PTA-yes and PTA-not groups. 
 
 N(%)* 
Characteristics PTA-yes 
(N=31) 
PTA-not 
(N=35) 
P-value 
Female  16 (51.6) 18 (51.4) 0.9 
Age, mean (SD), y 47.8 (10.2) 46.7 (11.7) 0.6 
EDSS score  
> 3.5 18 (58.1) 19 (54.3)  
< 3.5 13 (41.9) 16 (45.7)  
MS course  
Remitting Relapsing (RR) 16 (51.6) 21 (60) 0.6 
Primary Progressive (PP) 6 (19.4) 7 (20)  
Secondary Progressive (SP) 9 (29) 7 (20)  
Footnotes: 
*Percentage of column within group 
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Table 2. Results for Evoked Potentials (EP, Clinical-Functional measures (CFM) and Upper 
Limb Kinematic Measures (ULKM) derived composite functional outcomes. 
 
 No. (%)* 
Finding PTA-
yes 
(n=31) 
PTA-
not 
(n =35) 
Unadjusted 
Estimated Effect 
of Venous PTA 
OR (95% CI) ψ 
P-value Adjusted 
Estimated 
Effect of 
Venous PTA 
OR (95% CI) ϕ 
P-value 
a. EPs derived 
composite functional 
outcomeϖ 
 
Improved 11 (35) 7 (20) 1.03 (0.7-1.3) 0.82 1.26 (0.9-1.8) 0.18 
Stable 6 (19) 7 (20) NA    
Worsened 2 (6) 3 (9) NA    
Mixed 12 (39) 18 (51) NA    
b. CFM derived 
composite functional 
outcomeθ 
 
Improved 11 (35) 7 (20) 1.93 (1.3-2.8) 0.0007 1.85 (1.2-2.7) 0.002 
Stable 1 (3) 3 (9)     
Worsened 0 7 (20)     
Mixed 19 (61) 18 (51)     
c. ULKM derived 
composite functional 
outcome** 
 
 
Improved 9 (29) 10 (29) 1.16 (0.7-1.8) 0.5 1 (0.6-1.5) 0.96 
Stable 5 (16) 8 (23)     
Worsened 2 (6) 0     
Mixed 15 (48) 17 (49)     
Footnotes: 
*Percentage of column within group 
ψ Unadjusted OR for PTA-yes group improvement at 95%CI and P-value from logistic model. 
ϕ Adjusted logistic model was used for gender, MS course, both T0 and T1 EDSS raw data scores, both T0 and T1 EDSS > 
 3
3.5 and interactions 
ϖ All EPs single tests are included to obtain the EPs composite functional outcome 
θ CFM composite functional outcome is composed by the following tests: test#19, Trial Making Test-A (TMT-A); test #31, 
urinary urgency; test#35, Timed Up and Go (TUG); test#38, Fatigue Severity Scale (FSS); test#39, Numerical Rating Scale 
for pain (NRS); test#40, Hospital Anxiety-Depression Scale (HADS); test#41, HADS depression; test#43, physical Multiple 
Sclerosis Quality of life (MSQoL); test#44 mental MSQoL.  
** ULKM derived composite functional outcome is composed by the following test: test#45, MDE, right arm; test #47, PTV, 
right arm; test#49, AI, right arm; test#55, MDE, left arm; test#57, PTV, left arm; test#59, AI, left arm; test#63, MT, left arm. 
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Table 3. Detailed results for single components of Evoked Potentials (EPs) composite 
functional outcome. 
 
 T1*  
N(%)φ 
T0 
Score 
T1 
Score 
Functional 
assessment  
N I S W Median 
(range) 
Mean 
(SD) 
Median 
(range) 
Mean 
(SD) 
Test#1, VEP. 
Right Eye.60’ 
 
PTA-yes group 31 5 (16) 24 (77) 2 (6) 121 (113-
129) 
125 (19) 122 (115-
135) 
126 (18) 
PTA-not group 35 5 (14) 25 (71) 5 (14) 115 (105-
125) 
117 (15) 119 (103-
128) 
119 (19) 
Test#2, VEP. 
Left Eye.60’ 
 
PTA-yes group 31 6 (19) 19 (61) 6 (19) 119 (113-
135) 
127 (21) 117 (110-
133) 
122 (16) 
PTA-not group 35 8 (23) 24 (69) 3 (9) 115 (105-
122) 
118 (17) 119 (110-
130) 
121 (18) 
Test#3, VEP. 
Right Eye.15’ 
 
PTA-yes group 31 8 (26) 17 (55) 6 (19) 119 (113-
131) 
125 (20) 119 (113-
141) 
126 (19) 
PTA-not group 35  7 (20) 20 (57) 8 (23) 117 (105-
130) 
120 (18) 118 (105-
126) 
119 (19) 
Test#4, VEP. 
Left Eye. 15’ 
 
PTA-yes group 31 6 (19) 18 (58) 7 (23) 121 (112-
139) 
126 (21) 119 (109-
132) 
112 (15) 
PTA-not group 35 9 (26) 19 (54) 7 (20) 116 (105-
128) 
119 (17) 119 (110-
132) 
121(18) 
Test#5, MEP.  
 5
TMCT. Right 
upper arm 
PTA-yes group 31 5 (16) 20 (64) 6 (19) 23 (21-28) 25 (6) 22 (21-26) 24 (5) 
PTA-not group 35 4 (11) 30 (86) 1 (3) 21 (20-25) 23 (5) 23 (19-28) 24 (6) 
Test#6, MEP. 
TMCT. Left 
upper arm 
 
PTA-yes group 31 3 (10) 19 (61) 9 (29) 24 (21-28) 25 (6) 22 (19-27) 24 (6) 
PTA-not group 35 5 (14) 26 (74) 4 (11) 22 (20-26) 24 (5) 25 (20-27) 25 (6) 
Test#7, MEP. 
TMCT. Right 
lower leg 
 
PTA-yes group 31 7 (23) 20 (64) 4 (13) 35 (29-44) 38 (10) 37 (31-47) 39 (9) 
PTA-not group 35  5 (14) 27 (77) 3 (9) 35 (29-44) 36 (10) 36 (29-44) 37 (11) 
Test#8, MEP. 
TMCT. Left 
lower leg 
 
PTA-yes group 31 4 (13) 21 (68) 6 (19) 34 (31-48) 39 (9) 36 (30-46) 38 (19) 
PTA-not group 35 4 (11) 25 (71) 6 (17) 33 (28-38) 35 (9) 35 (27-51) 37 (13) 
Test#9, MEP. 
dCMCT. 
Right upper 
arm 
 
 
PTA-yes group 31 3 (10) 25(81) 3 (10) 9 (8-15) 12 (5) 10 (8-13) 12 (5) 
PTA-not group 35 3 (9) 31 (89) 1 (3) 9 (7-11) 10 (5) 10 (7-13) 11 (5) 
Test#10, 
MEP.dCMCT. 
Left upper 
arm 
 
 
PTA-yes group 31  1 (3) 27 (87) 3 (10) 11 (7-14) 12 (6) 10 (7-14) 11 (5) 
PTA-not group 35 5 (14) 28 (80) 2 (6) 9 (7-13) 10 (5) 11 (7-14) 12 (6) 
Test#11, 
MEP.dCMCT. 
 
 6
Right lower 
leg 
PTA-yes group 31 7 (23) 20 (64) 4 (13) 21 (14-30) 22 (9) 20 (16-32) 24 (9) 
PTA-not group 35 4 (11) 26 (74) 5 (14) 20 (14-31) 22 (9) 22 (14-28) 22 (9) 
Test#12, 
MEP.dCMCT. 
Left lower leg 
 
PTA-yes group 31 4 (13) 21 (68) 6 (19) 20 (16-32) 23 (9) 19 (14-33) 22 (10) 
PTA-not group 35 5 (14) 24 (69) 6 (17) 20 (13-24) 21 (9) 19 (14-30) 22 (10) 
Test#13, 
MEP.iCMCT. 
Right upper 
arm 
 
PTA-yes group 31 12 (39) 16 (51) 3 (10) 8 (6-12) 10 (5) 12 (8-14) 12 (5) 
PTA-not group 35 11 (31) 20 (57) 4 (11) 7 (5-8) 8 (5) 13 (7-16) 12 (5) 
Test#14, MEP. 
iCMCT. Left 
upper arm 
 
PTA-yes group 31 9 (29) 17 (55) 5 (16) 9 (6-12) 11 (6) 12 (8-14) 12 (7) 
PTA-not group 35 9 (26) 23 (66) 3 (9) 8 (6-11) 9 (4) 12 (7-15) 11 (4) 
Test#15, MEP. 
iCMCT. Right 
lower leg 
        
PTA-yes group 31 8 (26) 22 (71) 1 (3) 16 (15-28) 19 (8) 16 (15-28) 21 (9) 
PTA-not group 35 9 (26) 25 (71) 1 (3) 19 (12-27) 19 (8) 18 (16-22) 20 (7) 
Test#16, MEP. 
iCMCT. Left 
lower leg 
        
PTA-yes group 31 5 (16) 22 (71) 4 (13) 18 (14-24) 19 (6) 17 (15-28) 21 (9) 
PTA-not group 35 9 (26) 23 (66) 3 (9) 18 (11-21) 17 (6) 17 (14-24) 20 (8) 
Footnotes:  
* All P-value are >0.95 after adjustment for multiplicity with Hommel method 
φ Row percentage 
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Abbreviations. I:Improved; S:Stable; W:Worsened; VEP: Visual Evoked potential; 60’: 60 degree; 15’:15 degree; MEP: 
Motor Evoked potential; TMCT: total motor conduction time; dCMCT: direct central motor conduction time; iCMCT: 
indirect central motor conduction time 
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Table 4. Detailed results for single components of Clinical-Functional Measures (CFM) 
composite functional outcome. 
 
 T1*  
N(%)φ 
T0 
Score 
T1 
Score 
Functional 
assessment  
N I S W Median 
(range) 
Mean 
(SD) 
Median 
(range) 
Mean 
(SD) 
Test#19, 
TMT-A 
 
PTA-yes 
group 
31 15 (48) 8 (26) 8 (26) 58 (50-75) 63 (21) 54 (42-76) 63 (35) 
PTA-not 
group 
35 8 (23) 20 (57) 7 (20) 61 (53-87) 81 (68) 61 (52-74) 69 (33) 
Test#31, 
Urinary 
Urgency 
 
PTA-yes 
group 
31 8 (26) 22 (71) 1 (3) NA NA NA NA 
PTA-not 
group 
35 6 (17) 28 (80) 1 (3) NA NA NA NA 
Test#35, 
TUG 
 
PTA-yes 
group 
31 9 (29) 19 (61) 3 (10) 10 (8-30) 23 (22) 10 (8-25) 21 (22) 
PTA-not 
group 
35  5 (14) 27 (77) 3 (9) 11 (9-13) 19 (26) 10 (8-14) 19 (28) 
Test#38, FSS  
PTA-yes 
group 
31 6 (19) 23 (74) 2 (6) 47 (39-56) 45 (13) 44 (37-50) 42 (13) 
PTA-not 
group 
35 5 (14) 24 (69) 6 (17) 47 (26-55) 40 (17) 46 (23-56) 41(18) 
Test#39, NRS  
 9
for pain 
PTA-yes 
group 
31 12 (39) 14 (45) 5 (16) 2 (0-5) 3 (3) 1.5 (0-23) 2 (2) 
PTA-not 
group 
35 6 (17) 18 (51) 11 (31) 0.5 (0-3) 2 (2) 0 (0-5) 2 (3) 
Test#40, 
HADS-
anxiety 
 
PTA-yes 
group 
31 12 (43) 7 (25) 2 (32) 5 (2-8) 6 (4) 4 (3-6) 5 (3) 
PTA-not 
group 
35 12 (36) 8 (24) 13 (39) 5 (3-8) 6 (4) 6 (3-8) 6 (4) 
Test#41, 
HADS- 
depression  
 
PTA-yes 
group 
31 14 (45) 8 (26) 9 (29) 6 (4-9) 6 (4) 5 (3-7) 5 (3) 
PTA-not 
group 
35  17 (49) 7 (20) 11 (31) 8 (5-10) 7 (3) 6 (4-10) 7 (4) 
Test#43, 
MSQoL-
physical 
 
PTA-yes 
group 
31 8 (26) 22 (71) 1 (3) 52 (38-59) 48 (19) 55 (37-65) 53 (21) 
PTA-not 
group 
35 1 (3) 28 (80) 6 (17) 49 (38-71) 53 (21) 47 (36-73) 53 (23) 
Test#44, 
MSQoL-
mental 
 
 
PTA-yes 
group 
31 9 (29) 20 (64) 2 (6) 62 (44-76) 59 (20) 69 (51-83) 66 (20) 
PTA-not 
group 
35 4 (11) 23 (66) 8 (23) 62 (50-79) 64 (18) 65 (47-78) 61 (24) 
 10
Footnotes:  
* All P-value are >0.05 after adjustment for multiplicity with Hommel method 
φ Row percentage 
 
Abbreviations. I:Improved; S:Stable; W:Worsened; TMT-A: trial making tests-A; TUG: timed up and go; FSS: fatigue 
severity scale; NRS: Numerical rating scale for pain; HDS:Hospital Anxiety-Depression Scale; MSQoL; Multiple Sclerosis 
Quality of Life.  
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Table 5. Detailed results for single components of Upper Limb Kinematic Measures (ULKM) 
composite functional outcome. 
 T1*  
N(%)φ 
T0 
Score 
T1 
Score 
Functional 
assessment  
N I S W Median 
(range) 
Mean 
(SD) 
Median 
(range) 
Mean 
(SD) 
Test#45, 
MDE. Right 
        
PTA-yes 
group 
31 14 (45) 10 (32) 7 (23) 4 (2-8) 6 (6) 3 (1-5) 4 (3) 
PTA-not 
group 
35 10 (29) 18 (51) 7 (20) 3 (2-6) 6 (7) 3 (1-6) 5 (5) 
Test#47, 
PTV. Right 
        
PTA-yes 
group 
31 8 (26) 15 (48) 8 (26) 1122 
(890-
1656) 
1339 
(738) 
1138 
(880-
1711) 
1346 
(769) 
PTA-not 
group 
35 9 (26) 15 (43) 11 (31) 1238 
(906-
1685) 
1282 
(476) 
1105 
(761-
1643) 
1228 
(582) 
Test#49, AI. 
Right 
 
PTA-yes 
group 
31 5 (16) 22 (71) 4 (14) 0.9 (0.7-1) 0.9 (0.2) 0.9 (0.7-1) 0.9 (0.2) 
PTA-not 
group 
35 9 (26) 23 (66) 3 (9) 0.9 (0.7-1) 0.9 (0.3) 0.8 (0.7-1) 0.9 (0.3) 
Test#55, 
MDE. Left 
 
PTA-yes 
group 
31 11 (35) 10 (32) 10 (32) -1.6 [(-4)-
(-0.6)] 
-1.9 (4) -1.3 [(-4)-
(-0.6)] 
-1.7 (4) 
PTA-not 
group 
35 8 (23) 18 (51) 9 (26) -3.2 [(-7)-
(-2)] 
-5 (6) -3 [(-7)-(-
0.5)] 
-4 (5) 
 12
Test#57, 
PTV. Left 
 
PTA-yes 
group 
31 9 (29) 17 (55) 5 (16) 1103 
(768-
1816) 
1282 
(701) 
1260 
(779-
1819) 
1544 
(1214) 
PTA-not 
group 
35 8 (23) 13 (37) 14 (40) 1209 
(852-
1688) 
1311 
(497) 
1140 
(852-
1688) 
1214 
(603) 
Test#59, AI. 
Left  
        
PTA-yes 
group 
31 6 (19) 20 (64) 5 (16) 0.8 (0.6-1) 0.8 (0.2) 0.9 (0.8-1) 0.9 (0.2) 
PTA-not 
group 
35 10 (28) 22 (63) 3 (9) 0.8 (0.6-
0.9) 
0.9 (0.3) 0.8 (0.7-
0.9) 
0.8 (0.3) 
Test#63, MT. 
Left 
        
PTA-yes 
group 
31 7 (23) 24 (77) 0 730 (585-
1145) 
972 (533) 829 (587-
1131) 
886 (398) 
PTA-not 
group 
35 4 (11) 22 (63) 9 (26) 825 (636-
1037) 
842 (245) 930 (689-
1036) 
952 (404) 
Footnotes:  
* All P-value are >0.35 after adjustment for multiplicity with Hommel method 
φ Row percentage 
 
Abbreviations. I:Improved; S:Stable; W:Worsened; MDE: medium directional error; PTV: peak off tangential velocity; AI: 
Asymmetry index; MT: movement time. 
 
 
 
 
 

